daytrading march 28 pre-market, page-22

IPD - biotech

Brisbane, Australia - ImpediMed Limited (ASX:IPD) (“ImpediMed” or the “Company”) is pleased to announce that it has received binding commitments for a significantly
oversubscribed placement of shares with domestic and international institutional investors and sophisticated investors (the “Placement”). The Placement, which was strongly supported by both existing and new shareholders, is for approximately 45.3 million shares at A$0.195 per share, raising approximately A$8.8 million.

Morgans has a target range of 0.32-0.45 , Wilson HTM - 0.45 and Cannacord - 0.60